Pyrazolo[1,5-a]pyrimidines: Estrogen Receptor Ligands Possessing

2724

J. Med. Chem. 2005, 48, 2724

Additions and Corrections 2004, Volume 47 Dennis R. Compton, Shubin Sheng, Kathryn E. Carlson, Natalie A. Rebacz, In Young Lee, Benita S. Katzenellenbogen, and John A. Katzenellenbogen*: Pyrazolo[1,5-a]pyrimidines: Estrogen Receptor Ligands Possessing Estrogen Receptor β Antagonist Activity. Page 5877. In Table 1, the correct values of ERR and ERβ for compound 24b are 0.01 ( 0.001 and 0.36 ( 0.01, respectively. JM058162Z 10.1021/jm058162z Published on Web 02/05/2005

Thomas W. von Geldern,* Noah Tu, Philip R. Kym, James T. Link, Hwan-Soo Jae, Chunqiu Lai, Theresa Apelqvist, Patrik Rhonnstad, Lars Hagberg, Konrad Koehler, Marlena Grynfarb, Annika GoosNilsson, Johnny Sandberg, Marie O 2 sterlund, Tomas Barkhem, Marie Ho1 glund, Jiahong Wang, Steven Fung, Denise Wilcox, Phong Nguyen, Clarissa Jakob, Charles Hutchins, Mathias Fa1rnega˚ rdh, Bjo1 rn Kauppi, Lars O 2 hman, and Peer B. Jacobson: Liver-Selective Glucocorticoid Antagonists: A Novel Treatment for Type 2 Diabetes. Page 4223. The caption of Figure 7 incorrectly suggests that Sprague-Dawley rats were used in studies of HPA activation. Studies of HPA activation were performed using CD-1 mice (as described everywhere else in the manuscript). JM058170F 10.1021/jm058170f Published on Web 03/03/2005